Terms: = Prostate cancer AND PRF1, P14222, PFP, P1, MGC65093, HPLH2, FLH2, ENSG00000180644, 5551 AND Diagnosis
25 results:
1. The Effectiveness of prostate Imaging and Reporting and Data System Version 2 in the diagnosis of prostate cancer with Screening Parameters Correlation.
Arik ŞB; Güvenir D; Bozlar U; Taşar M; Turgut B
Arch Esp Urol; 2022 Jun; 75(5):416-422. PubMed ID: 35983812
[TBL] [Abstract] [Full Text] [Related]
2. Estrogen receptor β-targeted hypoxia-responsive near-infrared fluorescence probes for prostate cancer study.
Xie B; Meng Q; Yu H; Shen K; Cheng Y; Dong C; Zhou HB
Eur J Med Chem; 2022 Aug; 238():114506. PubMed ID: 35671592
[TBL] [Abstract] [Full Text] [Related]
3. GRP78-targeted and doxorubicin-loaded nanodroplets combined with ultrasound: a potential novel theranostics for castration-resistant prostate cancer.
Zhao Y; Shi D; Shang M; Sun X; Guo L; Meng D; Liu X; Zhou X; Li J
Drug Deliv; 2022 Dec; 29(1):203-213. PubMed ID: 34985396
[TBL] [Abstract] [Full Text] [Related]
4. PSMA-targeted melanin-like nanoparticles as a multifunctional nanoplatform for prostate cancer theranostics.
Dai L; Shen G; Wang Y; Yang P; Wang H; Liu Z
J Mater Chem B; 2021 Jan; 9(4):1151-1161. PubMed ID: 33434248
[TBL] [Abstract] [Full Text] [Related]
5. Structure-activity relationship studies of prostate-specific membrane antigen (PSMA) inhibitors derived from α-amino acid with (S)- or (R)-configuration at P1' region.
Kwon H; Lim H; Ha H; Choi D; Son SH; Nam H; Minn I; Byun Y
Bioorg Chem; 2020 Nov; 104():104304. PubMed ID: 33011530
[TBL] [Abstract] [Full Text] [Related]
6. The Identification of Key Gene Expression Signature in prostate cancer.
Huang Y; Cao Q; Song Z; Ruan H; Wang K; Chen K; Zhang X
Crit Rev Eukaryot Gene Expr; 2020; 30(2):153-168. PubMed ID: 32558494
[TBL] [Abstract] [Full Text] [Related]
7. Role of RUNX2 transcription factor in epithelial mesenchymal transition in non-small cell lung cancer lung cancer: Epigenetic control of the RUNX2 P1 promoter.
Herreño AM; Ramírez AC; Chaparro VP; Fernandez MJ; Cañas A; Morantes CF; Moreno OM; Brugés RE; Mejía JA; Bustos FJ; Montecino M; Rojas AP
Tumour Biol; 2019 May; 41(5):1010428319851014. PubMed ID: 31109257
[TBL] [Abstract] [Full Text] [Related]
8. Carcinosarcoma of the prostate: case report with molecular and histological characterization.
Salvi S; Casadio V; Martignano F; Gurioli G; Tumedei MM; Calistri D; Gunelli R; Costantini M
Int J Biol Markers; 2018 Nov; 33(4):540-544. PubMed ID: 30101629
[TBL] [Abstract] [Full Text] [Related]
9. Using Genetic and Epigenetic Markers to Improve Differential diagnosis of prostate cancer and Benign Prostatic Hyperplasia by Noninvasive Methods in Mexican Patients.
Sánchez BE; Aguayo A; Martínez B; Rodríguez F; Marmolejo M; Svyryd Y; Luna L; Muñoz LA; Jiménez MA; Sotomayor M; Vargas V F; Mutchinick OM
Clin Genitourin Cancer; 2018 Aug; 16(4):e867-e877. PubMed ID: 29571584
[TBL] [Abstract] [Full Text] [Related]
10. Electrochemical detection of methylated DNA on a microfluidic chip with nanoelectrokinetic pre-concentration.
Hong SA; Kim YJ; Kim SJ; Yang S
Biosens Bioelectron; 2018 Jun; 107():103-110. PubMed ID: 29453167
[TBL] [Abstract] [Full Text] [Related]
11. Molecular Diagnostic of prostate cancer From Body Fluids Using Methylation-Specific PCR (MS-PCR) Method.
Minciu R; Dumache R; Gheorghe P; Daminescu L; Rogobete AF; Ionescu D
Clin Lab; 2016; 62(6):1183-6. PubMed ID: 27468582
[TBL] [Abstract] [Full Text] [Related]
12. Activity of Artemisia annua and artemisinin derivatives, in prostate carcinoma.
Michaelsen FW; Saeed ME; Schwarzkopf J; Efferth T
Phytomedicine; 2015 Dec; 22(14):1223-31. PubMed ID: 26655404
[TBL] [Abstract] [Full Text] [Related]
13. The end of the road for prostate specific antigen testing?
Nna E
Niger J Clin Pract; 2013; 16(4):407-17. PubMed ID: 23974730
[TBL] [Abstract] [Full Text] [Related]
14. The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation.
De Nunzio C; Kramer G; Marberger M; Montironi R; Nelson W; Schröder F; Sciarra A; Tubaro A
Eur Urol; 2011 Jul; 60(1):106-17. PubMed ID: 21497433
[TBL] [Abstract] [Full Text] [Related]
15. Methylated genes as potential biomarkers in prostate cancer.
Phé V; Cussenot O; Rouprêt M
BJU Int; 2010 May; 105(10):1364-70. PubMed ID: 20067451
[TBL] [Abstract] [Full Text] [Related]
16. [Progress in studies of glutathione S-transferase P1 and prostate cancer].
Hou GF; Sui Y; An LW
Zhonghua Nan Ke Xue; 2006 Dec; 12(12):1113-5. PubMed ID: 17201261
[TBL] [Abstract] [Full Text] [Related]
17. Promoter hypermethylation of GSTP1, AR, and 14-3-3sigma in serum of prostate cancer patients and its clinical relevance.
Reibenwein J; Pils D; Horak P; Tomicek B; Goldner G; Worel N; Elandt K; Krainer M
Prostate; 2007 Mar; 67(4):427-32. PubMed ID: 17192910
[TBL] [Abstract] [Full Text] [Related]
18. Glutathione S-transferase M1, T1, and P1 polymorphisms and prostate cancer risk in middle-aged men.
Agalliu I; Langeberg WJ; Lampe JW; Salinas CA; Stanford JL
Prostate; 2006 Feb; 66(2):146-56. PubMed ID: 16173036
[TBL] [Abstract] [Full Text] [Related]
19. [Characteristics of methyl-specific PCR-test of glutathione-S-transferase P1 gene in plasm DNA and cellular urinary precipitate for differential diagnosis of prostatic adenoma and adenocarcinoma].
Likhin FA; Bartnovskiĭ AE; Vdovichenko KK; Abramov AA; Belokhvostov AS
Urologiia; 2005; (4):12-5. PubMed ID: 16158738
[TBL] [Abstract] [Full Text] [Related]
20. Gluthatione-S-transferase P1 polymorphism I105V in familial and sporadic prostate cancer.
Debes JD; Yokomizo A; McDonnell SK; Hebbring SJ; Christensen GB; Cunningham JM; Jacobsen SJ; Tindall DJ; Liu W; Schaid DJ; Thibodeau SN
Cancer Genet Cytogenet; 2004 Nov; 155(1):82-6. PubMed ID: 15527908
[TBL] [Abstract] [Full Text] [Related]
[Next]
